Skip to main content
. Author manuscript; available in PMC: 2021 Jan 6.
Published in final edited form as: Clin Lung Cancer. 2020 Aug 5;22(1):e57–e62. doi: 10.1016/j.cllc.2020.07.016

Table 2.

Univariate Cox Multivariate Cox
HR 95% CI p-value HR 95% CI p-value
Beta blocker use (yes vs. no) 0.58 0.33-0.99 0.046 0.48 0.23-1.01 0.054
Age (continuous) 0.99 0.97-1.01 0.360 0.98 0.98-1.02 0.195
Sex (male vs. female) 1.09 0.68-1.74 0.715 0.96 0.49-1.88 0.895
BMI (continuous) 0.96 0.92-0.99 0.027 0.97 0.93-1.02 0.263
Smoking (former or current vs. never) 0.94 0.54-1.64 0.833 0.85 0.39-1.82 0.670
ECOG performance status (0/1 vs. 2/3) 0.95 0.57-1.61 0.861 0.85 0.38-1.87 0.683
CNS metastasis (yes vs. no) 0.99 0.60-1.61 0.958 1.03 0.51-2.10 0.926
Tumor PD-L1 status (positive vs. negative) 0.45 0.23-0.87 0.017 0.57 0.26-1.26 0.166
Line of treatment (1st vs. 2nd or higher) 0.33 0.19-0.58 <0.001 0.33 0.13-0.87 0.025
Concurrent chemotherapy (yes vs. no) 0.42 0.15-1.15 0.092 0.40 0.08-2.04 0.270